Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim purchased 2,600 shares of the firm's stock in a transaction dated Monday, April 8th. The stock was purchased at an average cost of $13.57 per share, with a total value of $35,282.00. Following the acquisition, the director now directly owns 62,936 shares in the company, valued at $854,041.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Entrada Therapeutics Trading Down 5.7 %
Shares of Entrada Therapeutics stock traded down $0.76 during trading on Wednesday, reaching $12.52. The stock had a trading volume of 181,822 shares, compared to its average volume of 78,412. The company has a market capitalization of $420.67 million, a price-to-earnings ratio of -49.50 and a beta of -0.50. Entrada Therapeutics, Inc. has a 52 week low of $10.62 and a 52 week high of $18.44. The stock has a fifty day moving average price of $13.59 and a two-hundred day moving average price of $14.49.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings results on Wednesday, March 13th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.22). Entrada Therapeutics had a negative return on equity of 2.89% and a negative net margin of 5.18%. The firm had revenue of $41.85 million for the quarter, compared to analyst estimates of $27.82 million. On average, equities analysts forecast that Entrada Therapeutics, Inc. will post -1.54 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in TRDA. TD Asset Management Inc raised its position in shares of Entrada Therapeutics by 100.0% in the third quarter. TD Asset Management Inc now owns 119,254 shares of the company's stock valued at $1,884,000 after purchasing an additional 59,627 shares during the period. Wellington Management Group LLP grew its stake in Entrada Therapeutics by 2.6% in the 3rd quarter. Wellington Management Group LLP now owns 1,045,652 shares of the company's stock valued at $16,521,000 after buying an additional 26,144 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Entrada Therapeutics in the 3rd quarter valued at about $44,000. SG Americas Securities LLC acquired a new stake in Entrada Therapeutics during the third quarter worth approximately $145,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Entrada Therapeutics by 476.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,780 shares of the company's stock worth $87,000 after acquiring an additional 4,777 shares during the period. 86.39% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several research firms have weighed in on TRDA. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Entrada Therapeutics in a report on Monday, March 18th. Oppenheimer began coverage on shares of Entrada Therapeutics in a research note on Friday, January 5th. They issued an "outperform" rating and a $22.00 price target on the stock.
Read Our Latest Stock Report on TRDA
Entrada Therapeutics Company Profile
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Entrada Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.
While Entrada Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
